Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014646 · ClinicalTrials.gov registry record · Phase 2
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
A Phase 2 study of Smoldering Plasma Cell Myeloma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT05014646 is a Phase 2 study of Smoldering Plasma Cell Myeloma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 27 participants, below the 136-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05014646, a Phase 2 study of Smoldering Plasma Cell Myeloma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
Conditions Studied
Interventions
- DRUG Cholestyramine
- DRUG Leflunomide
Study Locations (4)
California
- City of Hope Medical Center - Duarte
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Atrium Health University City/LCI-University - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2027-01-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05014646
The ClinicalTrials.gov registry entry for NCT05014646 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (80% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoldering Plasma Cell Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Cholestyramine is the first listed.
NCT05014646 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT05014646 about?
NCT05014646 is a clinical study titled "Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients". This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and...
What is the current status of trial NCT05014646?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2022-03-07. Estimated completion is 2027-01-16.
What conditions does trial NCT05014646 study?
This clinical trial studies the following conditions: Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT05014646?
The interventions under investigation include: Cholestyramine (DRUG), Leflunomide (DRUG).
Who is sponsoring clinical trial NCT05014646?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05014646 being conducted?
This trial has 4 study locations across California, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
ACTIVE NOT RECRUITING · Phase 2
-
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
RECRUITING
-
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
RECRUITING · Phase 3
-
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
RECRUITING · NA
-
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.